title: HDACIs and the inhibition of invasive potential.
abstract: A major problem in the treatment of cancer and prolongation of patient survival is the dissemination of cells from a defined tumor site into a loco-regional disease and ultimately to full metastatic spread into distant organs. In the manuscript by Ierano et al. multiple chemically diverse histone deacetylase inhibitors (HDACIs) in tumor cell types of many diverse origins were shown to increase expression of the receptor CXCR4; a receptor whose expression promotes metastatic spread of tumor cells and that is correlated with a stage independent poor prognosis.(1,2) The ligand of CXCR4, CXCL12, also called stromal cell-derived factor (SDF1), stimulates signaling through multiple pathways downstream of the CXCR4 receptor including SRC kinases, ERK1/2, and STAT3. Inhibition of SRC, ERK, or STAT3 can all suppress tumor cell migration and reduce the threshold at which tumor cells undergo apoptosis.(3-8) The authors noted that despite increased CXCR4 expression following HDACI treatment, exogenous CXCL12 ligand had a reduced ability to stimulate cell signaling processes, with the phosphorylation of both SRC and STAT3 at activating sites declining. This resulted in less induced migration of HDACI-treated tumor cells. No studies were undertaken to determine whether HDACI-treated cells transduced to express activated forms of SRC or STAT3 or retained their invasive phenotype; however a loss of SRC and STAT3 signaling would predict for a less invasive phenotype.
authors: Department of Neurosurgery; Massey Cancer Center; Virginia Commonwealth University; Richmond, VA USA.
authors: Paul
authors: P
authors: Dent
mesh_terms: D005786:Gene Expression Regulation / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D012333:RNA, Messenger / Q000235:genetics*; D019718:Receptors, CXCR4 / Q000235:genetics* / Q000378:metabolism*
chemical_list: D056572:Histone Deacetylase Inhibitors; D012333:RNA, Messenger; D019718:Receptors, CXCR4
keywords: CXCL12; CXCR4; apicidin; entinostat; histone deacetylase inhibitor; romidepsin; vorinostat
references: Cancer Biol Ther. 2013 Sep;14(9):833-9
references: 23792588
references: Clin Cancer Res. 2013 Sep 1;19(17):4621-33
references: 23873690
references: Cancer Biol Ther. 2010 Jan;9(1):56-65
references: 19923906
references: Cancer Biol Ther. 2013 Mar;14(3):237-45
references: 23291984
references: Cancer Biol Ther. 2012 Jul;13(9):766-75
references: 22801507
references: Cancer Biol Ther. 2013 Feb;14(2):175-83
references: 23192271
references: Cancer Biol Ther. 2012 Apr;13(6):389-400
references: 22313638
references: Cancer Biol Ther. 2010 Jan;9(1):33-9
references: 19923918
references: Cancer Biol Ther. 2010 Jun 15;9(12):1000-7
references: 20364107